A recent study reveals that individuals who discontinue new weight-loss injections like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Published data in a leading health publication shows that while obese people can lose substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Users using such treatments must be informed of the risk of rapid rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment weight within about a year and a half.
Comparing Therapies
The research, which reviewed dozens of studies involving thousands of patients, compared the effects of the injectable medications with conventional dieting.
The team point out that individuals who shed pounds through lifestyle changes alone usually experience a less rapid weight regain—around 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Doctors propose the mode of action of the injections is key to understanding the heightened weight return.
These medications mimic a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of the hormone concentrations far above than normal could lead to the system to produce less of its own natural hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
The NHS suggest the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, given the high risk of relapse, the therapy might need to be long-term.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the persistent character of excess weight," akin to managing conditions like high blood pressure.
User Accounts
Individuals who have discontinued the jabs report a intense return of appetite.
"It was like a switch activating and I was suddenly extremely hungry," said a patient.
The struggle is compounded if individuals have not developed permanent lifestyle or habit changes during therapy.
Widespread Interest
Survey data show that millions of adults in the UK have tried these injections in the past year, with desire remaining high.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are potent agents for weight loss, they are not a magic solution and long-term success hinges on ongoing behavioural management.
